The Role of Concomitent MET Amplification and High PD-L1 Expression in Non-Small Cell Lung Cancer: A case report of Implications for Targeted Therapy and Immunotherapy

MET amplification occurs in approximately 1-5% of treatment-naïve non- small cell lung cancer (NSCLC) cases. It can also develop as an acquired resistance mechanism, particularly after treatment with EGFR tyrosine kinase inhibitors (TKIs), where it's observed in about 15% of cases. This case underscores the coexistence of MET gene amplification and high PD-L1 expression in NSCLC, which has significant therapeutic implications. The presence of MET amplification suggests potential benefit from MET- targeted therapies, while high PD-L1 expression indicates responsiveness to immune checkpoint inhibitors. When MET amplification and high PD-L1 co-exist, the optimal treatment strategy can be challenging. The integration of molecular and immunohistochemical data guides personalized treatment strategies for this patient.